Groupe hospitalier Diaconesses Croix Saint Simon

Clinical trials at this Paris hospital focus on neoplasms, especially cancers that require new treatment strategies or better ways to improve outcomes after surgery and standard therapy. The work in Service d'oncologie médicale centers on testing treatment effectiveness and refining care for patients with advanced disease.

• Triple Negative Breast Cancer (TNBC)
• Advanced ovarian, tubal, or peritoneal cancer
• Progression-free survival, event-free survival, and treatment response

This research includes studies of immunotherapy and chemotherapy combinations to improve cancer control and long-term outcomes in locally advanced breast cancer and other aggressive solid tumors.

The site also supports research in nutritional and metabolic diseases, with a focus on helping patients who have complex inherited conditions and limited treatment options. These trials aim to better understand treatment use in challenging medical settings and to confirm how therapies perform in people with significant kidney disease.

• Fabry Disease
• Amenable GLA variants
• Severe renal impairment and end-stage renal disease on hemodialysis

At Groupe hospitalier Diaconesses Croix Saint Simon, this area of research is centered on evaluating migalastat use, with attention to safety and how the body handles treatment in patients with advanced kidney involvement.

Another key area of activity is the study of treatment sequences for advanced ovarian cancer, including primary peritoneal cancer and fallopian tube cancer. These trials explore whether new combinations of established therapies can improve outcomes after complete surgery.

• First-line treatment strategies after surgery
• Maintenance therapy approaches
• Improving cancer control in advanced gynecologic malignancies

The goal of this research is to evaluate whether different treatment pathways can extend the time before disease progression and offer better long-term benefit for patients with advanced gynecologic cancers.